结节性痒疹的神经免疫发病机制研究进展

doi:10.35541/cjd.20240184

Abstract

Abstract: 【Abstract】 Prurigo nodularis is a chronic inflammatory skin disease with a complex etiology. Its pathogenesis primarily involves immune dysregulation, neuroimmune imbalance, fibroproliferation and their interactions. In recent years, the understanding of prurigo nodularis has been promoted by transcriptomic analyses and the development of new drugs. This review summarizes the latest research progress in the pathogenesis of prurigo nodularis, aiming to provide a reference for clinical diagnosis and treatment of as well as further research on prurigo nodularis.

Key words: Prurigo, Neuroimmunomodulation, Fibrosis, Prurigo nodularis

Song Xiaoting, Zhao Jiahui, Zhao Zuotao. Neuroimmune pathogenesis of prurigo nodularis[J]. Chinese Journal of Dermatology,2025,e20240184. doi:10.35541/cjd.20240184

References ［41］

［1］	Vasavda C, Wan G, Szeto MD, et al. A polygenic risk score for predicting racial and genetic susceptibility to prurigo nodularis［J］. J Invest Dermatol, 2023,143（12）:2416⁃2426.e1. doi: 10. 1016/j.jid.2023.04.033.
［2］	Williams J, Lowery Z, Bowers N, et al. Single⁃institution retrospective chart review of prurigo nodularis with a focus on etiology［J］. J Cutan Med Surg, 2022,26（6）:626⁃627. doi: 10. 1177/12034754221119501.
［3］	Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non⁃atopic diseases: aetiological survey in a consecutive cohort of 108 patients［J］. J Eur Acad Dermatol Venereol, 2013,27（5）:550⁃557. doi: 10.1111/j.1468⁃3083.2012. 04481.x.
［4］	Deng J, Parthasarathy V, Marani M, et al. Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis［J］. Front Med （Lausanne）, 2022,9:1022889. doi: 10.3389/fmed.2022.1022889.
［5］	Alkon N, Assen FP, Arnoldner T, et al. Single⁃cell RNA sequencing defines disease⁃specific differences between chronic nodular prurigo and atopic dermatitis［J］. J Allergy Clin Immunol, 2023,152（2）:420⁃435. doi: 10.1016/j.jaci.2023.04.019.
［6］	Kwatra SG. Breaking the itch⁃scratch cycle in prurigo nodularis［J］. N Engl J Med, 2020,382（8）:757⁃758. doi: 10.1056/NEJMe 1916733.
［7］	Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy［J］. Br J Dermatol, 2011,165（1）:85⁃91. doi: 10.1111/j.1365⁃2133.2011.10306.x.
［8］	Misery L. Chronic prurigo［J］. Br J Dermatol, 2022,187（4）:464⁃471. doi: 10.1111/bjd.21698.
［9］	Williams KA, Huang AH, Belzberg M, et al. Prurigo nodularis: pathogenesis and management［J］. J Am Acad Dermatol, 2020,83（6）:1567⁃1575. doi: 10.1016/j.jaad.2020.04.182.
［10］	Sutaria N, Alphonse MP, Roh YS, et al. Cutaneous transcriptomics identifies fibroproliferative and neurovascular gene dysregulation in prurigo nodularis compared with psoriasis and atopic dermatitis［J］. J Invest Dermatol, 2022,142（9）:2537⁃2540. doi: 10.1016/j.jid.2022.02.010.
［11］	Agrawal D, Sardana K, Mathachan SR, et al. A case⁃control study addressing the population of epidermal and dermal inflammatory infiltrate including neural milieu in primary prurigo nodularis using S⁃100 and toluidine blue stain and its therapeutic implications［J］. Int J Dermatol, 2023,62（11）:1352⁃1358. doi: 10.1111/ijd.16834.
［12］	Hashimoto T, Okuno S, Okuzawa M, et al. Increased sensitivity to touch⁃evoked itch （punctate hyperknesis） in prurigo nodularis and type 2 inflammation: a cross⁃sectional pilot study［J］. J Eur Acad Dermatol Venereol, 2023,37（6）:e789⁃e791. doi: 10.1111/jdv.18942.
［13］	Johansson O, Liang Y, Marcusson JA, et al. Eosinophil cationic protein⁃ and eosinophil⁃derived neurotoxin/eosinophil protein X⁃immunoreactive eosinophils in prurigo nodularis［J］. Arch Dermatol Res, 2000,292（8）:371⁃378. doi: 10.1007/s004030000142.
［14］	Shao Y, Zhu Y, Xiao Z, et al. RNA sequencing reveals the transcriptome profile of the atopic prurigo nodularis with severe itching［J］. Exp Dermatol, 2023,32（1）:30⁃40. doi: 10.1111/exd. 14678.
［15］	Meixiong J, Anderson M, Limjunyawong N, et al. Activation of mast⁃cell⁃expressed mas⁃related G⁃protein⁃coupled receptors drives non⁃histaminergic itch［J］. Immunity, 2019,50（5）:1163⁃1171.e5. doi: 10.1016/j.immuni.2019.03.013.
［16］	Shao Y, Xiao Z, Jin Y, et al. New insight into prurigo nodularis: proadrenomedullin N⁃terminal 20 peptide mediates mouse mast cell activation via Mrgprb2［J］. Skin Res Technol, 2024,30（2）:e13588. doi: 10.1111/srt.13588.
［17］	Kolkhir P, Pyatilova P, Ashry T, et al. Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo［J］. J Allergy Clin Immunol, 2022,149（6）:1998⁃2009.e5. doi: 10.1016/j.jaci.2022.02.021.
［18］	Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis［J］. Br J Dermatol, 2011,165（5）:990⁃996. doi: 10.1111/j.1365⁃2133. 2011.10498.x.
［19］	Belzberg M, Alphonse MP, Brown I, et al. Prurigo nodularis is characterized by systemic and cutaneous T helper 22 immune polarization［J］. J Invest Dermatol, 2021,141（9）:2208⁃2218.e14. doi: 10.1016/j.jid.2021.02.749.
［20］	Nemmer JM, Kuchner M, Datsi A, et al. Interleukin⁃31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues［J］. Front Med （Lausanne）, 2021,8:639097. doi: 10.3389/fmed.2021.639097.
［21］	Chaowattanapanit S, Wongjirattikarn R, Chaisuriya N, et al. Increased IL⁃31 expression in serum and tissue protein in prurigo nodularis［J］. Ther Adv Chronic Dis, 2022,13:204062 23221112561. doi: 10.1177/20406223221112561.
［22］	Kwatra SG, Yosipovitch G, Legat FJ, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis［J］. N Engl J Med, 2023,389（17）:1579⁃1589. doi: 10.1056/NEJMoa2301333.
［23］	Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double⁃blind, placebo⁃controlled phase 3 trials［J］. Nat Med, 2023,29（5）:1180⁃1190. doi: 10.1038/s41591⁃023⁃02320⁃9.
［24］	Gao Z, Dou Y, Zhao P, et al. Successful treatment of prurigo nodularis by dupilumab: report of 24 patients［J］. Dermatology, 2023,239（4）:658⁃663. doi: 10.1159/000529965.
［25］	Husein⁃ElAhmed H, Steinhoff M. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response［J］. J Dermatolog Treat, 2022,33（3）:1547⁃1553. doi: 10.1080/09546634.2020.1853024.
［26］	Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron⁃expressed IL⁃31 receptor mediates T helper cell⁃dependent itch: Involvement of TRPV1 and TRPA1［J］. J Allergy Clin Immunol, 2014,133（2）:448⁃460. doi: 10.1016/j.jaci.2013.10.048.
［27］	Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co⁃opt classical immune signaling pathways to mediate chronic itch［J］. Cell, 2017,171（1）:217⁃228.e13. doi: 10.1016/j.cell.2017.08.006.
［28］	Kolkhir P, Akdis CA, Akdis M, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs［J］. Nat Rev Drug Discov, 2023,22（9）:743⁃767. doi: 10.1038/s41573⁃023⁃00750⁃1.
［29］	Parthasarathy V, Cravero K, Xu L, et al. The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: a cluster analysis［J］. J Am Acad Dermatol, 2023,88（5）:1101⁃1109. doi: 10.1016/j.jaad.2023.01.042.
［30］	Wong LS, Yen YT, Lin SH, et al. IL⁃17A induces endothelin⁃1 expression through p38 pathway in prurigo nodularis［J］. J Invest Dermatol, 2020,140（3）:702⁃706.e2. doi: 10.1016/j.jid.2019. 08.438.
［31］	Agelopoulos K, Renkhold L, Wiegmann H, et al. Transcriptomic, epigenomic, and neuroanatomic signatures differ in chronic prurigo, atopic dermatitis, and brachioradial pruritus［J］. J Invest Dermatol, 2023,143（2）:264⁃272.e3. doi: 10.1016/j.jid.2022. 08.042.
［32］	Haas S, Capellino S, Phan NQ, et al. Low density of sympathetic nerve fibers relative to substance P⁃positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis［J］. J Dermatol Sci, 2010,58（3）:193⁃197. doi: 10.1016/j.jdermsci. 2010.03.020.
［33］	Assas BM, Pennock JI, Miyan JA. Calcitonin gene⁃related peptide is a key neurotransmitter in the neuro⁃immune axis［J］. Front Neurosci, 2014,8:23. doi: 10.3389/fnins.2014.00023.
［34］	Fowler E, Yosipovitch G. Chronic itch management: therapies beyond those targeting the immune system［J］. Ann Allergy Asthma Immunol, 2019,123（2）:158⁃165. doi: 10.1016/j.anai. 2019.01.016.
［35］	Pogatzki⁃Zahn EM, Pereira MP, Cremer A, et al. Peripheral sensitization and loss of descending inhibition is a hallmark of chronic pruritus［J］. J Invest Dermatol, 2020,140（1）:203⁃211.e4. doi: 10.1016/j.jid.2019.05.029.
［36］	Issa NT, Riva H, Jafferany M. Prurigo nodularis: current clinicopathologic overview and psychodermatological perspectives［J］. J Drugs Dermatol, 2023,22（12）:SF365502s6⁃SF365502s11. doi: 10.36849/JDD.SF365502.
［37］	Weigelt N, Metze D, Ständer S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients［J］. J Cutan Pathol, 2010,37（5）:578⁃586. doi: 10.1111/j.1600⁃0560.2009. 01484.x.
［38］	Liu S, Hur YH, Cai X, et al. A tissue injury sensing and repair pathway distinct from host pathogen defense［J］. Cell, 2023,186（10）:2127⁃2143.e22. doi: 10.1016/j.cell.2023.03.031.
［39］	Patel JR, Joel MZ, Lee KK, et al. Single⁃cell RNA sequencing reveals dysregulated POSTN+WNT5A+ fibroblast subclusters in prurigo nodularis［J］. J Invest Dermatol, 2024,144（7）:1568⁃1578.e5. doi: 10.1016/j.jid.2023.12.021.
［40］	Hashimoto T, Nattkemper LA, Kim HS, et al. Dermal periostin: a new player in itch of prurigo nodularis［J］. Acta Derm Venereol, 2021,101（1）:adv00375. doi: 10.2340/00015555⁃3702.
［41］	Hashimoto T, Mishra SK, Olivry T, et al. Periostin, an emerging player in itch sensation［J］. J Invest Dermatol, 2021,141（10）:2338⁃2343. doi: 10.1016/j.jid.2021.03.009.

[1]	Xia Manqi, Shao Lei, Huang Qiongxiao, Tian Xin, Liang Yimin, Huang Ting, Liang Jingyao, Liu Yumei. Efficacy and safety of dupilumab in the treatment of prurigo nodularis: a multicenter retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(8): 679-684.
[2]	Tian Jing, Deng Sisi, Song Zhiqiang . A comparison of clinical characteristics between atopic and non-atopic prurigo nodularis [J]. Chinese Journal of Dermatology, 2024, 57(4): 331-337.
[3]	Huang Wenhua, Zheng Zhenlong, Jin Zhehu. Role of transforming growth factor-β/Smad pathway and related factors in the pathogenesis of keloids [J]. Chinese Journal of Dermatology, 2023, 0(2): 20220556-e20220556.
[4]	Cheng Bihong, Dou Xia. Diagnosis and classification of chronic prurigo [J]. Chinese Journal of Dermatology, 2023, 56(11): 1070-1073.
[5]	Gao Zirui, Zhao Pei, Dou Yuanqing, Liu Ping, Zhang Jianzhong. Efficacy and safety of dupilumab in the treatment of adult prurigo nodularis [J]. Chinese Journal of Dermatology, 2022, 55(7): 562-565.
[6]	Song Xiaoting, Liu Bo, Chen Yudi, Zhao Zuotao. Pathophysiological pathogenesis of rosacea [J]. Chinese Journal of Dermatology, 2022, 55(5): 446-449.
[7]	Yu Su, Yu Tianze, Li Wei. Role of the autonomic nervous system in immune imbalance in atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 362-365.
[8]	Song Haifeng, Dong Gaohong, Wei Kaijun, Hu Xinhong, Zhang Yanguo, Liu Tao. Tension promotes keloid fibrosis: a preliminary study [J]. Chinese Journal of Dermatology, 2021, 54(3): 196-200.
[9]	Wen Guangdong, Zhong Zhaohui, Mao Dandan, Yao Xueyan, Zhang Jianzhong. Clinical analysis of six cases of prurigo pigmentosa associated with ketogenic diet and bariatric surgery [J]. Chinese Journal of Dermatology, 2021, 54(2): 122-126.
[10]	Zheng Yucan, Kong Guiping, Jin Yu, Li Mei. A case of hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis caused by a mutation in the FAM111B gene [J]. Chinese Journal of Dermatology, 2021, 54(11): 973-977.
[11]	LU Dong-Qing, CHEN Hong-Duo, WANG Ya-Kun. Immunoohenotyping of the skin lesions in neuroderanatitis and prurigo nodularis [J]. Chinese Journal of Dermatology, 1993, 26(2): 90-92.

Neuroimmune pathogenesis of prurigo nodularis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［41］

Related Articles 11

Metrics

Comments

Recommended 10